Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent

References

• Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 1976;36:2807–2812.
   PubMed Web of Science ®Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture Cancer Res. 1986;46:467–473.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark G, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005;11:416–420.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520–11539.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther. 2015;153:107–124.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Web Site. Available from: http://www.cancer.gov/clinicaltrials
   Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol. 2000;57:5–12.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980;6:1507–1515.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Chaplin DJ, Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res. 1990;50:7430–7436.
   PubMed Web of Science ®Google Scholar
• von der Maase H. Effect of cancer chemotherapeutic drugs on the radiation-induced skin reactions in mouse feet. Br J Radiol. 1984;57:697–707.
   PubMed Web of Science ®Google Scholar
• Lundbeck F, Ulsø N, Overgaard J. Cystometric evaluation of early and late irradiation damage to the mouse urinary bladder. Radiother Oncol. 1989;15:383–392.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW, Chaplin DJ, et al. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol. 1997;45:167–174.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Overgaard J, Vaeth M. Effect of cancer chemotherapeutic drugs on the radiation-induced lung damage in mice. Radiother Oncol. 1986;5:245–257.
   PubMed Web of Science ®Google Scholar
• Wittenborn TR, Horsman MR. Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy. Acta Oncol. 2015;54:1385–1392.
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol. 2001;60:155–161.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Murata R, Maxwell RJ, et al. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys. 2008;70:859–866.
   PubMed Web of Science ®Google Scholar
• Iversen AB, Busk M, Horsman MR. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol. 2013;52:1320–1326.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Khalil AA, Nordsmark M, et al. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiother Oncol. 1993;28:69–71.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Khalil AA, Siemann DW, et al. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys. 1994;29:439–442.
   PubMed Web of Science ®Google Scholar
• Bentzen L, Keiding S, Horsman MR, et al. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements: influence of tumour volumes and carbogen breathing. Acta Oncol. 2002;41:304–312.
   PubMed Web of Science ®Google Scholar
• Bentzen L, Keiding S, Horsman MR, et al. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography: a study evaluating [18F]fluoromisonidazole and [18F]fluoro-2-deoxy-d-glucose. Acta Oncol. 2000;39:629–637.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423–435.
   PubMed Web of Science ®Google Scholar
• Dark GD, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res. 1997;57:1829–1834.
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol. 2001;77:195–204.
   PubMed Web of Science ®Google Scholar